Not only incretins for diabetic kidney disease —beneficial effects by DPP-4 inhibitors
Incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, are secreted in response to high blood glucose levels and stimulate insulin release from pancreatic β cells. Under normal conditions, GLP-1 is rapidly degraded at the N-terminus by dipeptidylpeptidase-4 (DPP-4). To overcome this rapid degradation, both pharmacologic inhibition of DPP-4 and DPP-4‒resistant GLP-1 analogs with extended half-life in the body were developed for the purpose of treat ing type 2 diabetes mellitus.
Source: Kidney International - Category: Urology & Nephrology Authors: Masaomi Nangaku, Christoph Wanner Tags: Controversies in Nephrology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Hormones | Incretin Therapy | Insulin | Pancreas | Urology & Nephrology